Clinical observation of Cinacalcet in the treatment of secondary hyperparathyroidism in hemodialysis patients

Objective To discuss the clinical effects of Cinacalcet——a calcium sensitive receptor agonist in maintenance hemodialysis (MDH) patients with secondary hyperparathyroidism (SHPT).Methods Ninety-eight MDH patients with SHPT admitted at the Fifth Hospital of Wuhan were divided into the observation group (n=49) and the control group (n=49). The patients in the control group were treated with conventional treatments such as phosphate binding agent, vitamin D analogue, and those in the observation group were given Cinacalcet besides the treatments in the control group. The clinical effects were compared between the two groups. The changes in blood urea nitrogen, creatinine and KT/V were compared between the two groups.Results The effective rate in the observation group was 87.8%, significantly higher than 67.3% in the control group (P<0.05). Blood calcium phosphorus, ALP, and iPTH levels in the two groups were significantly reduced after the treatment (P<0.01), and those in the observation group were significantly lower than in the control group (P<0.01). There was no significantly difference in BUN, SCr, and KT/V between the two groups (P>0.05). The size of the parathyroid glands was significantly smaller after treatment than before treatment in both two groups (P<0.01), and that in the observation group was significantly smaller than in the control group (P<0.01). The incidence of adverse reactions in the observation group was 14.3%, significantly lower than 40.8% in the control group (P<0.01).Conclusions Cinacalcet has exactly effective in MDH patients with SHPT. Cinacalcet can effectively reduce the level of parathyroid hormone and the size of the parathyroid glands, with less adverse reactions, and is worthy of promotion.